The final overall survival (OS) analysis of data from the phase III EXAM trial reveal no siginificant improvement in OS with the tyrosine-kinase inhibitor cabozantinib, relative to placebo, in unselected patients with progressive medullary thyroid cancer. However, in an exploratory analysis, selected patients with tumours harbouring the RETM918Tmutation had a significant improvement in median OS in response to cabozantinib (44.3 months, versus 18.9 months in patients receiving placebo; P = 0.03), indicating that cabozantinib is an effective treatment of patients with RETM918T-positive disease.
References
Schlumberger, M. et al. Overall survival analysis of EXAM, a phase 3 trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdx479 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Cabozantinib effective in selected patients. Nat Rev Clin Oncol 14, 712 (2017). https://doi.org/10.1038/nrclinonc.2017.163
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.163